- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00045201
Clorhidrato de erlotinib e clorhidrato de irinotecán en el tratamiento de pacientes con tumores sólidos avanzados
Ensayo de fase I de OSI-774 y CPT-11 en pacientes con tumores sólidos avanzados
Phase I trial to study the effectiveness of combining erlotinib hydrochloride with irinotecan hydrochloride in treating patients who have advanced solid tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib hydrochloride and chemotherapy may kill more tumor cells.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) of erlotinib (erlotinib hydrochloride) and irinotecan (irinotecan hydrochloride), in relation to presence or absence of UGT1A1*28 polymorphism, in patients with advanced solid tumors that overexpress epidermal growth factor receptor.
II. Determine the dose-limiting toxicity of these regimens in these patients. III. Determine whether erlotinib alters the disposition of irinotecan using a previously described limited sampling model.
IV. Determine factors that influence the disposition of these drugs, including genetic variation in UGT1A1 and BCRP, in patients treated with these regimens.
V. Determine factors that influence the disposition of these drugs, in terms of tumor BCRP-expression, in tumor samples from patients treated with these drugs at the MTD.
VI. Evaluate the effect of this regimen on epidermal growth factor receptor phosphorylation in these patients.
VII. Assess, preliminarily, any antitumor activity in patients treated with these regimens.
VIII. Correlate, preliminarily, EGFR phosphorylation and/or BCRP -expression with response in tumor samples from these patients.
OUTLINE: This is a dose-escalation study. Patients are stratified according to UGTA1A genotype (all patients regardless of genotype [closed to accrual as of 9/15/04] vs UGT1A1 6/6 genotype vs UGTA1A 6/7 or 7/7 genotype).
Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride intravenously (IV) over 90 minutes on day 1 and oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients per stratum receive escalating doses of erlotinib hydrochloride and irinotecan hydrochloride until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the MTD.
Patients are followed for 3 months.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed malignancy that overexpresses epidermal growth factor receptor (EGFR)
- Unresectable disease for which there is no known standard therapy that ispotentially curative or definitely capable of extending life expectancy
- UGT1A1 genotype 6/6, 6/7, or 7/7
- Willing to provide biologic specimens
- Lesions amenable for 2 biopsies from the same tumor site (only patients receiving MTD in groups 2 and 3)
- No known brain metastases
- Performance status - ECOG 0-2
- At least 12 weeks
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9.0 g/dL
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST ≤ 2.5 times ULN (5 times ULN if liver metastases present)
- Creatinine no greater than 1.5 times ULN
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No New York Heart Association class III or IV heart disease
- No gastrointestinal tract disease resulting in an inability to take oral or nasogastric medication
- No requirement for IV alimentation
- No active peptic ulcer disease
- No abnormalities of the cornea (e.g., dry eye syndrome or Sjögren's syndrome)
- No congenital abnormality (e.g., Fuch's dystrophy)
- No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
- No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)
- No other uncontrolled concurrent illness
- No ongoing or active infection
- No significant traumatic injury within the past 21 days
- No seizure disorder
- No psychiatric illness or social situation that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No concurrent grapefruit or grapefruit juice
- No smoking during study
- More than 4 weeks since prior immunotherapy or biologic therapy
- No concurrent immunotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No other concurrent chemotherapy
- Not specified
- More than 4 weeks since prior radiotherapy
- No prior radiotherapy to more than 25% of bone marrow
- No concurrent radiotherapy
- More than 3 weeks since prior major surgery
- No prior surgical procedures affecting absorption
- No prior EGFR-targeting therapy (e.g., gefitinib or EKB-569)
- No other concurrent investigational therapy
- No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine, or valproic acid)
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent enrollment on another study involving pharmacological agents for symptom control or therapeutic intent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment (enzyme inhibitor, chemotherapy)
Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Otros nombres:
Given orally
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Efecto de erlotinib sobre la fosforilación de EGFR en MTD
Periodo de tiempo: Semanalmente durante el curso 1
|
Semanalmente durante el curso 1
|
|
|
Expresión tumoral de BCRP en pacientes atendidos en el MTD
Periodo de tiempo: Semanalmente durante el curso 1
|
Semanalmente durante el curso 1
|
|
|
MTD of erlotinib hydrochloride and irinotecan hydrochloride in patients with advanced solid tumors that overexpress epidermal growth factor receptor
Periodo de tiempo: At least 4 weeks
|
Defined as the highest safely tolerated dose where at most one patient experiences DLT with the next higher dose having at least 2 patients who experience DLT. Three patients will be entered at a given dose level and observed for at least 4 weeks to assess toxicity. MTD will be determined independently for each cohort. |
At least 4 weeks
|
|
Dose limiting toxicity of the combination in all cohorts
Periodo de tiempo: At least 4 weeks
|
Defined as an adverse event attributed (definitely, probably, or possibly) to the study treatment. Graded using the National Cancer Institute Common Toxicity Criteria (CTC) version 2.0. Defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE) versioun 4.0. |
At least 4 weeks
|
|
Effect of erlotinib hydrochloride on the disposition of irinotecan hydrochloride
Periodo de tiempo: Weekly during course 1
|
Analysis performed using high performance liquid chromatography assays. Serial blood samples will be obtained during Cycle 1 only to determine the pharmacokinetics of irinotecan hydrochloride and erlotinib hydrochloride. |
Weekly during course 1
|
|
Genetic variation in UGT1A1 and BCRP
Periodo de tiempo: Weekly during course 1
|
Detected using allele-specific restriction fragment length polymorphism (RFLP) assays and GeneScan assays. The overall incidence of UTG1A1 polymorphism will be estimated and summarized. |
Weekly during course 1
|
|
Evidence of anti tumor activity
Periodo de tiempo: Every 3 weeks
|
Evaluated using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. |
Every 3 weeks
|
|
Correlation of EGFR phosphorylation and/or BCRP expression with response to this combination
Periodo de tiempo: Every 3 weeks
|
Evaluated using modified RECIST criteria. |
Every 3 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Henry C Pitot, Mayo Clinic
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NCI-2009-00015
- P30CA015083 (Subvención/contrato del NIH de EE. UU.)
- U01CA069912 (Subvención/contrato del NIH de EE. UU.)
- NCI-2009-00015 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- CDR0000256910
- 594-02 01
- NCI-5351
- MAYO-MC0112
- MC0112 (Otro identificador: Mayo Clinic in Rochester)
- 5351 (Otro identificador: CTEP)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .